Collegium Pharmaceutical (COLL) Financials

$34.07 -0.35 (-1.02%)

Closing price 05/22/2026 04:00 PM Eastern

Extended Trading

$34.22 +0.15 (+0.43%)

As of 05/22/2026 07:51 PM Eastern

Annual Income Statements for Collegium Pharmaceutical

This table shows Collegium Pharmaceutical's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Income / (Loss) Attributable to Common Shareholders	-27	-94	-75	-39	-23	27	72	-25	48	69	63
Consolidated Net Income / (Loss)	-27	-94	-75	-39	-23	27	72	-25	48	69	63
Net Income / (Loss) Continuing Operations	-27	-94	-75	-39	-23	27	72	-25	48	69	63
Total Pre-Tax Income	-27	-94	-75	-39	-23	28	-3.37	-29	76	99	93
Total Operating Income	-27	-94	-75	-21	-24	56	18	33	167	170	180
Total Gross Profit	0.00	1.50	26	115	103	180	151	209	326	377	463
Total Revenue	0.00	1.71	28	280	297	310	277	464	567	631	781
Operating Revenue	0.00	1.71	28	280	297	310	277	464	567	631	781
Total Cost of Revenue	0.00	0.21	2.60	166	194	130	126	254	241	254	317
Operating Cost of Revenue	0.00	0.21	2.60	166	194	130	126	254	241	254	317
Total Operating Expenses	27	96	101	135	127	124	133	176	159	207	284
Selling, General & Admin Expense	19	81	93	127	116	114	119	172	159	210	285
Other Special Charges / (Income)	-	-	-	-	0.00	0.00	-	0.00	0.00	-2.91	-1.18
Total Other Income / (Expense), net	-0.35	-0.09	0.58	-18	1.03	-29	-21	-62	-91	-71	-87
Interest Expense	-0.09	0.09	-	20	0.91	29	21	63	107	85	98
Interest & Investment Income	-0.44	-	0.58	1.69	1.94	0.23	0.01	1.05	16	14	11
Income Tax Expense	-	-	-	0.00	0.00	0.83	-75	-3.85	28	29	30
Basic Earnings per Share	($1.48)	($3.88)	($2.47)	($1.19)	($0.68)	$0.78	$2.05	($0.74)	$1.43	$2.14	$1.98
Weighted Average Basic Shares Outstanding	13.54M	24.26M	30.27M	32.95M	33.45M	34.41M	34.94M	33.83M	33.74M	32.27M	31.71M
Diluted Earnings per Share	($1.48)	($3.88)	($2.47)	($1.19)	($0.68)	$0.76	$1.86	($0.74)	$1.29	$1.86	$1.73
Weighted Average Diluted Shares Outstanding	13.54M	24.26M	30.27M	32.95M	33.45M	35.15M	41.05M	33.83M	41.79M	40.42M	39.70M
Weighted Average Basic & Diluted Shares Outstanding	13.54M	24.26M	30.27M	32.95M	33.45M	34.76M	33.38M	34.07M	31.96M	31.49M	31.75M

This table shows Collegium Pharmaceutical's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
Net Income / (Loss) Attributable to Common Shareholders	21	32	28	20	9.34	13	2.42	12	32	17	14
Consolidated Net Income / (Loss)	21	32	28	20	9.34	13	2.42	12	32	17	14
Net Income / (Loss) Continuing Operations	21	32	28	20	9.34	13	2.42	12	32	17	14
Total Pre-Tax Income	29	47	37	29	16	17	3.12	17	43	29	19
Total Operating Income	45	62	49	47	35	38	22	35	62	61	31
Total Gross Profit	80	95	91	91	97	98	97	108	129	128	117
Total Revenue	137	150	145	145	159	182	178	188	209	205	194
Operating Revenue	137	150	145	145	159	182	178	188	209	205	194
Total Cost of Revenue	56	55	53	54	63	84	80	80	80	77	76
Operating Cost of Revenue	56	55	53	54	63	84	80	80	80	77	76
Total Operating Expenses	35	33	42	43	62	60	76	73	67	68	86
Selling, General & Admin Expense	35	33	42	43	62	63	76	74	67	68	86
Other Special Charges / (Income)	-	-	0.00	0.00	0.00	-	-0.79	-0.36	-0.02	-0.02	0.00
Total Other Income / (Expense), net	-16	-15	-13	-18	-19	-21	-19	-18	-19	-32	-12
Interest Expense	21	19	17	23	23	23	21	20	22	35	16
Interest & Investment Income	4.54	4.30	4.49	4.40	3.28	1.81	2.23	2.38	3.12	3.57	3.71
Income Tax Expense	8.15	15	8.91	9.49	6.25	4.73	0.71	5.04	12	12	4.24
Basic Earnings per Share	$0.61	$0.95	$0.86	$0.60	$0.29	$0.39	$0.08	$0.38	$1.00	$0.52	$0.45
Weighted Average Basic Shares Outstanding	33.74M	33.74M	32.33M	32.43M	32.26M	32.27M	31.79M	31.81M	31.57M	31.71M	32.09M
Diluted Earnings per Share	$0.53	$0.93	$0.71	$0.52	$0.27	$0.36	$0.07	$0.34	$0.84	$0.48	$0.40
Weighted Average Diluted Shares Outstanding	42.06M	41.79M	41.44M	40.38M	40.16M	40.42M	32.84M	39.08M	39.44M	39.70M	40.07M
Weighted Average Basic & Diluted Shares Outstanding	32.61M	31.96M	32.72M	32.21M	32.25M	31.49M	32.14M	31.50M	31.61M	31.75M	32.43M

This table details how cash moves in and out of Collegium Pharmaceutical's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Change in Cash & Equivalents	94	58	-35	28	23	6.64	12	-13	64	-143	156
Net Cash From Operating Activities	-22	-75	-67	169	28	94	104	124	275	205	329
Net Cash From Continuing Operating Activities	-22	-75	-67	169	28	94	104	124	275	205	328
Net Income / (Loss) Continuing Operations	-27	-94	-75	-39	-23	27	72	-25	48	69	63
Consolidated Net Income / (Loss)	-27	-94	-75	-39	-23	27	72	-25	48	69	63
Depreciation Expense	0.17	0.66	0.59	1.07	0.73	0.87	1.74	2.68	3.50	3.86	4.18
Amortization Expense	-0.03	-0.03	-0.03	110	15	70	71	145	153	169	226
Non-Cash Adjustments To Reconcile Net Income	2.22	5.79	26	140	30	21	65	0.35	47	48	61
Changes in Operating Assets and Liabilities, net	3.34	13	-18	-42	5.42	-24	-105	1.66	23	-85	-26
Net Cash From Investing Activities	-0.36	-2.98	-0.99	-24	-6.44	-374	-1.94	-574	-71	-288	-64
Net Cash From Continuing Investing Activities	-0.36	-2.98	-0.99	-24	-6.44	-374	-1.94	-574	-71	-288	-64
Purchase of Property, Plant & Equipment	-0.36	-0.48	-0.99	-5.48	-6.44	-5.55	-1.94	-1.62	-0.46	-1.65	-1.74
Acquisitions	0.00	-2.50	-	-19	0.00	-368	0.00	-572	0.00	-268	0.00
Purchase of Investments	-	-	-	-	-	-	0.00	0.00	-92	-111	-127
Sale and/or Maturity of Investments	-	-	-	-	-	-	0.00	0.00	22	93	65
Net Cash From Financing Activities	116	136	33	-117	2.04	286	-89	437	-140	-61	-110
Net Cash From Continuing Financing Activities	116	136	33	-117	2.04	286	-89	437	-140	-61	-110
Repayment of Debt	-1.36	-2.67	-2.67	0.00	0.00	-49	-50	-75	-301	-272	-636
Repurchase of Common Equity	-	-	-	-0.03	0.00	0.00	-48	-14	-75	-60	-25
Issuance of Debt	0.00	-	-	10	0.00	330	0.00	518	235	0.00	565
Issuance of Common Equity	72	138	35	1.12	0.82	0.76	0.76	0.34	0.46	0.83	1.36
Other Financing Activities, net	0.52	0.44	0.67	-128	1.22	4.32	7.80	7.77	0.28	271	-16
Cash Interest Paid	0.35	0.28	0.14	-	0.71	19	18	53	73	62	69
Cash Income Taxes Paid	-	-	-	0.00	0.00	0.48	3.01	10	24	52	60

This table details how cash moves in and out of Collegium Pharmaceutical's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
Net Change in Cash & Equivalents	-25	-20	-10	-56	-109	32	20	21	33	81	37
Net Cash From Operating Activities	74	73	62	67	-9.00	85	55	72	78	123	57
Net Cash From Continuing Operating Activities	74	73	62	67	-9.47	85	55	72	78	122	57
Net Income / (Loss) Continuing Operations	21	32	28	20	9.34	13	2.42	12	32	17	14
Consolidated Net Income / (Loss)	21	32	28	20	9.34	13	2.42	12	32	17	14
Depreciation Expense	0.84	0.95	0.92	0.95	0.95	1.04	1.09	1.14	1.03	0.92	0.46
Amortization Expense	38	36	36	35	41	57	57	57	57	56	56
Non-Cash Adjustments To Reconcile Net Income	39	-11	-2.00	36	10	4.23	13	3.50	12	33	10
Changes in Operating Assets and Liabilities, net	-24	15	-0.58	-24	-71	11	-17	-0.75	-23	15	-24
Net Cash From Investing Activities	-3.82	-25	-18	-8.91	-249	-12	-9.68	-2.92	-31	-20	1.63
Net Cash From Continuing Investing Activities	-3.82	-25	-18	-8.91	-249	-12	-9.68	-2.92	-31	-20	1.63
Purchase of Property, Plant & Equipment	-0.07	-0.16	-0.57	-0.27	-0.24	-0.57	-0.80	-0.07	-0.19	-0.69	-0.27
Purchase of Investments	-9.76	-41	-39	-34	-11	-27	-26	-17	-45	-39	-18
Sale and/or Maturity of Investments	6.00	16	22	26	29	16	17	14	15	20	20
Net Cash From Financing Activities	-95	-68	-54	-114	149	-41	-25	-48	-15	-22	-21
Net Cash From Continuing Financing Activities	-95	-68	-54	-114	149	-41	-25	-48	-15	-22	-21
Repayment of Debt	-46	-46	-46	-79	-165	17	-16	-16	-16	-587	-7.25
Issuance of Common Equity	0.29	-	0.36	-	0.47	-	0.51	-	0.86	-	0.95
Other Financing Activities, net	0.13	3.01	-8.67	-0.16	0.01	280	-9.60	-7.12	0.47	0.12	-15
Cash Interest Paid	20	16	17	12	18	15	22	14	22	12	22
Cash Income Taxes Paid	7.28	6.91	0.17	36	16	0.62	2.46	30	15	12	0.04

This table presents Collegium Pharmaceutical's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Total Assets	98	162	136	291	306	644	692	1,174	1,143	1,664	1,657
Total Current Assets	97	159	133	238	256	278	316	420	538	482	691
Cash & Equivalents	96	153	119	147	170	174	186	174	239	71	231
Restricted Cash	-	-	-	-	-	-	-	-	0.00	25	20
Short-Term Investments	-	-	-	-	-	-	-	0.00	72	92	155
Accounts Receivable	0.00	2.13	9.97	78	73	83	106	183	180	229	211
Inventories, net	0.00	1.32	1.81	7.82	9.64	16	17	47	32	36	41
Prepaid Expenses	1.19	1.91	3.01	5.12	3.11	4.84	5.88	17	15	30	33
Plant, Property, & Equipment, net	0.74	1.04	1.83	9.27	12	19	19	20	16	14	12
Total Noncurrent Assets	0.10	2.40	0.26	44	39	347	357	735	590	1,167	953
Goodwill	0.00	2.10	-	44	30	336	0.00	134	134	162	146
Intangible Assets	-	-	-	-	-	-	269	567	422	891	670
Noncurrent Deferred & Refundable Income Taxes	-	-	-	-	-	-	78	24	26	98	113
Other Noncurrent Operating Assets	0.00	0.20	0.16	0.20	9.23	8.51	7.73	6.96	7.90	15	25
Total Liabilities & Shareholders' Equity	98	162	136	291	306	644	692	1,174	1,143	1,664	1,657
Total Liabilities	13	27	31	200	219	458	489	979	948	1,435	1,355
Total Current Liabilities	8.43	26	31	189	202	239	280	434	458	510	440
Short-Term Debt	2.67	-	1.48	1.64	3.83	47	48	163	183	94	47
Accounts Payable	3.54	9.11	5.68	12	6.25	10	4.19	3.49	8.69	3.93	11
Accrued Expenses	2.23	8.88	24	175	191	181	226	267	265	411	381
Current Deferred Revenue	0.00	7.61	-	-	-	-	-	-	-	0.00	0.67
Other Current Liabilities	-	-	-	-	0.66	0.73	0.81	1.11	0.99	1.27	1.41
Total Noncurrent Liabilities	4.21	1.51	0.00	11	17	218	210	546	490	925	915
Long-Term Debt	4.15	1.48	-	9.86	7.67	210	202	538	484	788	780
Noncurrent Deferred Revenue	-	-	-	-	-	-	-	-	0.00	10	9.11
Other Noncurrent Operating Liabilities	0.07	0.03	-	0.68	9.44	8.77	7.95	7.11	6.12	127	126
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	-	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	85	135	104	92	87	186	203	195	195	229	302
Total Preferred & Common Equity	85	135	104	92	87	186	203	195	195	229	302
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	-	0.00	0.00	0.00	0.00
Total Common Equity	85	135	104	92	87	186	203	195	195	229	302
Common Stock	214	358	402	429	447	519	502	538	566	590	625
Retained Earnings	-129	-223	-298	-337	-360	-333	-256	-281	-233	-164	-101
Treasury Stock	-0.00	-	-	-	-	-	-43	-62	-137	-198	-223
Accumulated Other Comprehensive Income / (Loss)	-	-	-	-	-	-	-	0.00	0.01	0.06	0.32

This table presents Collegium Pharmaceutical's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024	Q1 2025	Q2 2025	Q3 2025	Q1 2026
Period end date	9/30/2022	3/31/2023	6/30/2023	9/30/2023	3/31/2024	6/30/2024	9/30/2024	3/31/2025	6/30/2025	9/30/2025	3/31/2026
Total Assets	1,201	1,214	1,214	1,178	1,114	1,053	1,635	1,631	1,593	1,607	1,652
Total Current Assets	405	498	537	537	539	510	444	528	549	614	746
Cash & Equivalents	134	269	284	259	229	173	39	96	117	150	269
Restricted Cash	-	-	-	-	-	-	25	20	20	20	20
Short-Term Investments	-	-	42	46	89	99	81	102	105	136	153
Accounts Receivable	195	179	167	182	175	184	228	229	213	234	229
Inventories, net	65	33	26	34	31	28	38	37	38	38	43
Prepaid Expenses	11	17	18	17	15	27	32	44	56	36	33
Plant, Property, & Equipment, net	20	19	18	17	15	15	15	14	13	12	12
Total Noncurrent Assets	776	697	659	624	560	528	1,177	1,090	1,031	981	895
Goodwill	130	134	134	134	134	134	146	151	148	146	146
Intangible Assets	610	530	493	456	387	353	947	836	780	725	614
Noncurrent Deferred & Refundable Income Taxes	26	24	25	26	31	34	73	92	92	102	114
Other Noncurrent Operating Assets	7.12	6.75	6.53	6.98	6.77	6.45	11	12	10	7.82	21
Total Liabilities & Shareholders' Equity	1,201	1,214	1,214	1,178	1,114	1,053	1,635	1,631	1,593	1,607	1,652
Total Liabilities	1,004	1,035	1,013	999	892	837	1,401	1,397	1,360	1,333	1,340
Total Current Liabilities	414	413	435	465	446	462	459	487	465	453	435
Short-Term Debt	142	183	183	183	183	183	94	89	65	65	50
Accounts Payable	7.64	2.99	2.42	3.65	6.02	2.41	3.14	18	11	7.65	6.83
Accrued Expenses	264	225	248	277	256	275	361	378	370	361	376
Current Deferred Revenue	-	-	-	-	-	-	-	-	-	0.67	0.67
Other Current Liabilities	1.18	1.04	0.97	0.96	1.01	1.04	1.27	1.30	19	19	1.45
Total Noncurrent Liabilities	589	622	578	534	446	375	941	910	896	880	905
Long-Term Debt	582	615	571	528	440	369	803	773	758	744	770
Noncurrent Deferred Revenue	-	-	-	-	-	-	10	10	10	9.28	8.94
Other Noncurrent Operating Liabilities	7.35	6.87	6.63	6.38	5.86	5.59	129	127	127	127	125
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	197	180	201	179	222	217	234	234	232	275	312
Total Preferred & Common Equity	197	180	201	179	222	217	234	234	232	275	312
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	197	180	201	179	222	217	234	234	232	275	312
Common Stock	526	540	549	546	565	568	583	593	599	615	622
Retained Earnings	-274	-299	-286	-265	-205	-186	-177	-162	-150	-118	-87
Treasury Stock	-54	-62	-62	-102	-137	-165	-172	-198	-218	-223	-223
Accumulated Other Comprehensive Income / (Loss)	-	-	-0.04	-0.05	-0.12	-0.18	0.39	0.24	0.34	0.29	-0.22

This table displays calculated financial ratios and metrics derived from Collegium Pharmaceutical's official financial filings.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
DEI Shares Outstanding	-	-	-	-	-	-	-	-	-	-	31,610,976.00
DEI Adjusted Shares Outstanding	-	-	-	-	-	-	-	-	-	-	31,610,976.00
DEI Earnings Per Adjusted Shares Outstanding	-	-	-	-	-	-	-	-	-	-	1.99
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	0.00%	0.00%	1,564.29%	884.73%	5.81%	4.49%	-10.69%	67.56%	22.17%	11.41%	23.62%
EBITDA Growth	-16,831.25%	-249.13%	19.87%	220.48%	-109.16%	1,633.62%	-29.04%	100.71%	79.25%	6.00%	19.51%
EBIT Growth	0.00%	-249.66%	19.81%	72.58%	-14.81%	336.79%	-68.65%	89.01%	401.10%	1.76%	5.73%
NOPAT Growth	0.00%	-249.66%	19.81%	72.58%	-14.81%	428.09%	-77.38%	89.01%	355.18%	12.34%	2.25%
Net Income Growth	0.00%	-245.54%	20.51%	47.74%	41.93%	217.74%	167.33%	-134.96%	292.60%	43.68%	-9.13%
EPS Growth	93.49%	-162.16%	36.34%	51.82%	42.86%	211.76%	144.74%	-139.78%	274.32%	44.19%	-6.99%
Operating Cash Flow Growth	-20.17%	-248.00%	10.71%	352.75%	-83.60%	238.13%	10.24%	19.96%	121.16%	-25.39%	60.66%
Free Cash Flow Firm Growth	-1,774.46%	-232.82%	-6.97%	128.02%	-31.06%	-2,692.71%	105.25%	-3,009.78%	163.31%	-191.79%	228.35%
Invested Capital Growth	-312.34%	-333.23%	21.85%	-229.04%	-63.24%	474.83%	-0.94%	172.62%	-23.28%	67.11%	-21.73%
Revenue Q/Q Growth	0.00%	319.36%	49.99%	28.76%	0.26%	0.67%	-15.01%	28.27%	3.68%	5.37%	3.10%
EBITDA Q/Q Growth	-346.59%	-89.35%	39.88%	97.42%	-148.44%	35.35%	-36.07%	68.46%	14.63%	-0.83%	5.81%
EBIT Q/Q Growth	-351.30%	-89.23%	39.88%	58.02%	-128.92%	44.69%	-73.59%	365.28%	42.67%	-12.19%	14.43%
NOPAT Q/Q Growth	-275.91%	-89.23%	39.88%	58.02%	-128.92%	40.34%	-92.36%	365.28%	113.62%	-10.94%	7.45%
Net Income Q/Q Growth	-2,060.79%	-16.53%	11.95%	40.37%	-98.71%	52.06%	-30.91%	41.63%	434.11%	-21.90%	7.57%
EPS Q/Q Growth	78.83%	-108.60%	17.11%	39.90%	-106.06%	55.10%	-29.01%	32.11%	760.00%	-23.46%	7.45%
Operating Cash Flow Q/Q Growth	-6.79%	-23.64%	12.97%	48.84%	-48.94%	7.95%	15.15%	32.01%	2.62%	5.84%	13.20%
Free Cash Flow Firm Q/Q Growth	0.00%	-93.29%	37.59%	115.43%	-90.04%	2.74%	-91.72%	19.78%	9.69%	6.01%	0.21%
Invested Capital Q/Q Growth	13.44%	-41.28%	-42.42%	-174.03%	-22.40%	-1.95%	3.92%	-8.23%	-5.52%	-6.39%	-7.10%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	0.00%	87.55%	90.89%	40.92%	34.73%	58.01%	54.40%	45.15%	57.55%	59.76%	59.35%
EBITDA Margin	0.00%	-5,462.36%	-262.98%	32.18%	-2.79%	40.89%	32.49%	38.92%	57.10%	54.33%	52.52%
Operating Margin	0.00%	-5,498.66%	-264.95%	-7.38%	-8.00%	18.14%	6.37%	7.18%	29.46%	26.91%	23.01%
EBIT Margin	0.00%	-5,498.66%	-264.95%	-7.38%	-8.00%	18.14%	6.37%	7.18%	29.46%	26.91%	23.01%
Profit (Net Income) Margin	0.00%	-5,504.15%	-262.91%	-13.95%	-7.66%	8.63%	25.83%	-5.39%	8.50%	10.96%	8.05%
Tax Burden Percent	100.00%	100.00%	100.00%	100.00%	100.00%	96.99%	-2,119.65%	86.67%	63.59%	70.20%	67.88%
Interest Burden Percent	101.29%	100.10%	99.23%	189.16%	95.68%	49.05%	-19.14%	-86.58%	45.36%	58.02%	51.56%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	3.01%	0.00%	0.00%	36.41%	29.80%	32.12%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	55.83%	4.65%	4.74%	16.70%	16.18%	14.83%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	0.00%	127.00%	88.33%	-11.76%	3.53%	6.64%	4.23%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	0.00%	-36.27%	32.12%	-17.31%	7.98%	16.44%	8.87%
Return on Equity (ROE)	-74.84%	-85.62%	-62.65%	-39.99%	-25.39%	19.57%	36.77%	-12.57%	24.68%	32.62%	23.70%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	-106.21%	5.60%	-87.91%	43.04%	-34.07%	39.21%
Operating Return on Assets (OROA)	0.00%	-72.44%	-50.71%	-9.69%	-7.95%	11.84%	2.64%	3.57%	14.41%	12.11%	10.82%
Return on Assets (ROA)	0.00%	-72.52%	-50.32%	-18.34%	-7.61%	5.63%	10.71%	-2.68%	4.16%	4.93%	3.79%
Return on Common Equity (ROCE)	4.39%	-85.62%	-62.65%	-39.99%	-25.39%	19.57%	36.77%	-12.57%	24.68%	32.62%	23.70%
Return on Equity Simple (ROE_SIMPLE)	-32.04%	-69.81%	-71.93%	-42.72%	-25.99%	14.38%	35.24%	-12.83%	24.64%	30.23%	0.00%
Net Operating Profit after Tax (NOPAT)	-19	-66	-53	-14	-17	55	12	23	106	119	122
NOPAT Margin	0.00%	-3,849.06%	-185.46%	-5.16%	-5.60%	17.59%	4.46%	5.03%	18.73%	18.89%	15.62%
Net Nonoperating Expense Percent (NNEP)	-21.68%	-23.52%	-16.39%	-19.53%	-4.15%	-71.17%	-83.68%	16.50%	13.16%	9.53%	10.60%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-	-	2.60%	12.31%	10.74%	10.80%
Cost of Revenue to Revenue	0.00%	12.45%	9.11%	59.08%	65.27%	41.99%	45.60%	54.85%	42.45%	40.24%	40.65%
SG&A Expenses to Revenue	0.00%	4,712.57%	325.73%	45.20%	39.25%	36.72%	42.97%	37.11%	28.09%	33.31%	36.49%
R&D to Revenue	0.00%	873.64%	30.10%	3.09%	3.49%	3.15%	3.41%	0.86%	0.00%	0.00%	0.00%
Operating Expenses to Revenue	0.00%	5,586.21%	355.84%	48.29%	42.73%	39.87%	48.03%	37.97%	28.09%	32.85%	36.34%
Earnings before Interest and Taxes (EBIT)	-27	-94	-75	-21	-24	56	18	33	167	170	180
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-27	-93	-75	90	-8.27	127	90	181	324	343	410
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	6.69	3.30	5.78	6.23	7.89	3.72	3.18	4.00	5.14	4.04	4.85
Price to Tangible Book Value (P/TBV)	6.69	3.35	5.78	12.06	11.91	0.00	0.00	0.00	0.00	0.00	0.00
Price to Revenue (P/Rev)	0.00	260.35	21.11	2.04	2.33	2.23	2.33	1.68	1.77	1.46	1.88
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	25.89	9.03	0.00	20.84	13.35	23.28
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	3.86%	11.08%	0.00%	4.80%	7.49%	4.30%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	0.00	0.00	2.91	2.69	1.82	2.46	1.75	2.61
Enterprise Value to Revenue (EV/Rev)	0.00	171.67	16.99	1.55	1.79	2.50	2.56	2.82	2.40	2.56	2.41
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	4.83	0.00	6.12	7.89	7.23	4.20	4.72	4.60
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	13.79	40.24	39.20	8.15	9.52	10.49
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	14.22	57.48	56.00	12.81	13.56	15.45
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	2.57	19.13	8.26	6.85	10.51	4.95	7.89	5.72
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	27.52	48.69	0.00	47.74	0.00	4.97	0.00	5.84
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.08	0.01	0.01	0.13	0.13	1.38	1.23	3.60	3.41	3.85	2.74
Long-Term Debt to Equity	0.05	0.01	0.00	0.11	0.09	1.13	0.99	2.76	2.48	3.44	2.59
Financial Leverage	-1.07	-1.09	-1.13	-1.29	-1.64	-0.29	0.36	1.47	2.26	2.48	2.10
Leverage Ratio	1.41	1.18	1.25	2.18	3.34	3.47	3.43	4.69	5.94	6.62	6.26
Compound Leverage Factor	1.43	1.18	1.24	4.13	3.19	1.70	-0.66	-4.06	2.69	3.84	3.23
Debt to Total Capital	7.41%	1.08%	1.40%	11.16%	11.62%	58.02%	55.19%	78.25%	77.34%	79.39%	73.27%
Short-Term Debt to Total Capital	2.90%	0.00%	1.40%	1.59%	3.87%	10.72%	10.68%	18.14%	21.25%	8.42%	4.13%
Long-Term Debt to Total Capital	4.51%	1.08%	0.00%	9.56%	7.75%	47.30%	44.52%	60.11%	56.09%	70.96%	69.14%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	92.59%	98.92%	98.60%	88.84%	88.38%	41.98%	44.81%	21.75%	22.66%	20.61%	26.73%
Debt to EBITDA	-0.25	-0.02	-0.02	0.13	-1.39	2.03	2.78	3.88	2.06	2.57	2.02
Net Debt to EBITDA	3.32	1.62	1.57	-1.50	19.18	0.65	0.71	2.92	1.10	2.02	1.03
Long-Term Debt to EBITDA	-0.15	-0.02	0.00	0.11	-0.93	1.65	2.24	2.98	1.50	2.30	1.90
Debt to NOPAT	-0.36	-0.02	-0.03	-0.79	-0.69	4.71	20.26	30.05	6.28	7.39	6.78
Net Debt to NOPAT	4.72	2.30	2.22	9.33	9.54	1.52	5.15	22.61	3.36	5.82	3.45
Long-Term Debt to NOPAT	-0.22	-0.02	0.00	-0.68	-0.46	3.84	16.34	23.09	4.56	6.61	6.40
Altman Z-Score	25.32	7.01	7.65	1.02	1.17	1.02	0.82	0.62	1.41	0.95	1.57
Noncontrolling Interest Sharing Ratio	105.87%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	11.49	6.20	4.24	1.26	1.27	1.16	1.13	0.97	1.17	0.95	1.57
Quick Ratio	11.35	6.07	4.09	1.19	1.20	1.08	1.05	0.82	1.07	0.77	1.36
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-16	-53	-57	16	11	-283	15	-432	274	-251	322
Operating Cash Flow to CapEx	-5,957.73%	-15,734.38%	-6,769.49%	3,092.75%	431.55%	1,693.87%	5,327.01%	7,659.06%	59,598.48%	12,407.99%	18,926.61%
Free Cash Flow to Firm to Interest Expense	0.00	-562.04	0.00	0.79	12.01	-9.80	0.71	-6.84	2.56	-2.94	3.28
Operating Cash Flow to Interest Expense	0.00	-798.44	0.00	8.41	30.56	3.25	4.93	1.97	2.57	2.40	3.35
Operating Cash Flow Less CapEx to Interest Expense	0.00	-803.51	0.00	8.14	23.48	3.06	4.84	1.94	2.57	2.38	3.33
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.00	0.01	0.19	1.31	0.99	0.65	0.41	0.50	0.49	0.45	0.47
Accounts Receivable Turnover	0.00	0.00	4.71	6.38	3.93	3.97	2.93	3.21	3.13	3.09	3.55
Inventory Turnover	0.00	0.00	1.66	34.41	22.18	10.31	7.65	7.96	6.10	7.49	8.30
Fixed Asset Turnover	0.00	1.93	19.89	50.52	28.09	20.10	14.39	23.78	31.93	41.66	59.26
Accounts Payable Turnover	0.00	0.03	0.35	18.58	21.05	16.01	17.78	66.24	39.49	40.25	43.49
Days Sales Outstanding (DSO)	0.00	0.00	77.53	57.22	92.82	91.99	124.69	113.67	116.77	117.94	102.84
Days Inventory Outstanding (DIO)	0.00	0.00	220.05	10.61	16.45	35.41	47.71	45.83	59.80	48.76	43.98
Days Payable Outstanding (DPO)	0.00	10,832.62	1,040.14	19.64	17.34	22.80	20.53	5.51	9.24	9.07	8.39
Cash Conversion Cycle (CCC)	0.00	-10,832.62	-742.55	48.18	91.93	104.60	151.87	153.99	167.33	157.63	138.43
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	-3.91	-17	-13	-44	-71	266	264	720	552	923	722
Invested Capital Turnover	0.00	-0.16	-1.89	-9.88	-5.18	3.17	1.04	0.94	0.89	0.86	0.95
Increase / (Decrease) in Invested Capital	-2.96	-13	3.70	-30	-28	338	-2.52	456	-168	370	-200
Enterprise Value (EV)	480	294	484	436	531	776	709	1,306	1,360	1,618	1,884
Market Capitalization	569	445	601	571	690	693	646	779	1,004	924	1,464
Book Value per Share	$4.11	$4.72	$3.20	$2.75	$2.61	$5.38	$5.87	$5.80	$5.99	$7.10	$9.54
Tangible Book Value per Share	$4.11	$4.64	$3.20	$1.42	$1.73	($4.33)	($1.90)	($15.08)	($11.04)	($25.58)	($16.25)
Total Capital	92	136	106	103	99	443	453	896	863	1,110	1,129
Total Debt	6.81	1.48	1.48	12	12	257	250	701	667	881	827
Total Long-Term Debt	4.15	1.48	0.00	9.86	7.67	210	202	538	484	788	780
Net Debt	-89	-152	-117	-135	-159	83	64	527	357	694	420
Capital Expenditures (CapEx)	0.36	0.48	0.99	5.48	6.44	5.55	1.94	1.62	0.46	1.65	1.74
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-4.58	-20	-15	-97	-112	-88	-102	-25	-48	-121	-109
Debt-free Net Working Capital (DFNWC)	91	133	103	50	58	86	84	149	263	66	298
Net Working Capital (NWC)	88	133	102	48	54	38	36	-14	80	-27	251
Net Nonoperating Expense (NNE)	8.42	28	22	25	6.10	28	-59	48	58	50	59
Net Nonoperating Obligations (NNO)	-89	-152	-117	-135	-159	80	61	525	357	694	420
Total Depreciation and Amortization (D&A)	0.14	0.62	0.56	111	15	71	72	147	157	173	230
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	-1,183.28%	-53.46%	-34.45%	-37.83%	-28.45%	-36.88%	-5.37%	-8.39%	-19.24%	-13.91%
Debt-free Net Working Capital to Revenue	0.00%	7,772.00%	363.38%	17.84%	19.48%	27.72%	30.46%	32.07%	46.41%	10.50%	38.17%
Net Working Capital to Revenue	0.00%	7,772.00%	358.18%	17.26%	18.19%	12.40%	12.99%	-2.96%	14.06%	-4.32%	32.21%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($1.48)	($3.88)	($2.47)	($1.19)	($0.68)	$0.00	$0.00	$0.00	$1.43	$2.14	$1.98
Adjusted Weighted Average Basic Shares Outstanding	23.51M	29.45M	32.99M	33.31M	34.05M	0.00	0.00	0.00	33.74M	32.27M	31.71M
Adjusted Diluted Earnings per Share	($1.48)	($94,176,000.00)	($2.47)	($1.19)	($0.68)	$0.00	$0.00	$0.00	$1.29	$1.86	$1.73
Adjusted Weighted Average Diluted Shares Outstanding	23.51M	29.45M	32.99M	33.31M	34.05M	0.00	0.00	0.00	41.79M	40.42M	39.70M
Adjusted Basic & Diluted Earnings per Share	($1.48)	($94,176,000.00)	($2.47)	($1.19)	($0.68)	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	13.54M	24.26M	30.27M	32.95M	33.45M	0.00	0.00	0.00	31.96M	31.49M	31.75M
Normalized Net Operating Profit after Tax (NOPAT)	-19	-66	-53	-14	-17	55	16	23	106	117	121
Normalized NOPAT Margin	0.00%	-3,849.06%	-185.46%	-5.16%	-5.60%	17.59%	5.61%	5.03%	18.73%	18.56%	15.52%
Pre Tax Income Margin	0.00%	-5,504.15%	-262.91%	-13.95%	-7.66%	8.90%	-1.22%	-6.22%	13.36%	15.61%	11.87%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	-1,000.87	0.00	-1.03	-26.13	1.95	0.84	0.53	1.56	1.99	1.83
NOPAT to Interest Expense	0.00	-700.61	0.00	-0.72	-18.29	1.89	0.59	0.37	0.99	1.40	1.24
EBIT Less CapEx to Interest Expense	0.00	-1,005.95	0.00	-1.30	-33.21	1.75	0.75	0.50	1.56	1.97	1.81
NOPAT Less CapEx to Interest Expense	0.00	-705.69	0.00	-0.99	-25.37	1.70	0.49	0.34	0.99	1.38	1.22
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	-0.08%	0.00%	0.00%	66.92%	-56.25%	155.75%	86.75%	39.93%

This table displays calculated financial ratios and metrics derived from Collegium Pharmaceutical's official financial filings.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
DEI Shares Outstanding	-	-	-	-	-	-	-	-	-	31,610,976.00	31,753,211.00
DEI Adjusted Shares Outstanding	-	-	-	-	-	-	-	-	-	31,610,976.00	31,753,211.00
DEI Earnings Per Adjusted Shares Outstanding	-	-	-	-	-	-	-	-	-	0.54	0.46
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	7.63%	15.53%	0.11%	7.18%	16.53%	21.51%	22.66%	29.41%	31.42%	12.92%	8.87%
EBITDA Growth	37.30%	72.15%	32.33%	10.07%	-7.69%	-2.92%	-8.09%	10.72%	54.90%	23.52%	10.31%
EBIT Growth	119.93%	424.69%	100.89%	33.22%	-22.60%	-38.22%	-56.16%	-26.05%	78.21%	59.42%	42.46%
NOPAT Growth	394.04%	412.54%	117.17%	22.82%	-35.31%	-34.41%	-55.15%	-22.75%	115.75%	28.30%	42.34%
Net Income Growth	4,415.10%	543.67%	259.03%	50.73%	-54.76%	-60.75%	-91.28%	-38.88%	237.51%	35.31%	499.75%
EPS Growth	5,200.00%	542.86%	239.22%	52.94%	-49.06%	-61.29%	-90.14%	-34.62%	211.11%	33.33%	471.43%
Operating Cash Flow Growth	73.06%	10.57%	123.83%	-32.41%	-112.16%	15.42%	-10.56%	7.48%	971.63%	45.37%	3.10%
Free Cash Flow Firm Growth	144.32%	146.87%	30.40%	-23.74%	-263.89%	-263.48%	-254.69%	-277.56%	166.60%	168.84%	163.01%
Invested Capital Growth	-25.48%	-23.28%	-25.47%	-21.03%	68.66%	67.11%	67.06%	63.70%	-21.13%	-21.73%	-21.37%
Revenue Q/Q Growth	0.86%	9.54%	-3.22%	0.24%	9.65%	14.22%	-2.30%	5.76%	11.36%	-1.87%	-5.81%
EBITDA Q/Q Growth	9.94%	17.71%	-12.45%	-2.84%	-7.80%	23.80%	-17.12%	17.04%	28.99%	-1.28%	-25.98%
EBIT Q/Q Growth	26.32%	37.04%	-19.80%	-4.05%	-26.61%	9.39%	-43.10%	61.87%	76.86%	-2.14%	-49.15%
NOPAT Q/Q Growth	23.91%	30.72%	-11.25%	-14.56%	-34.74%	32.53%	-39.31%	47.16%	82.27%	-21.19%	-32.67%
Net Income Q/Q Growth	58.64%	54.79%	-13.23%	-29.25%	-52.39%	34.29%	-80.72%	395.78%	162.93%	-46.16%	-14.54%
EPS Q/Q Growth	55.88%	75.47%	-23.66%	-26.76%	-48.08%	33.33%	-80.56%	385.71%	147.06%	-42.86%	-16.67%
Operating Cash Flow Q/Q Growth	-25.78%	-0.92%	-15.55%	8.82%	-113.35%	1,040.59%	-34.55%	30.76%	8.28%	56.87%	-53.58%
Free Cash Flow Firm Q/Q Growth	7.71%	-9.64%	3.11%	-24.39%	-331.48%	9.86%	1.96%	13.20%	186.83%	-6.83%	-10.26%
Invested Capital Q/Q Growth	-7.11%	-5.52%	-4.50%	-5.60%	98.39%	-6.39%	-4.71%	-7.50%	-4.42%	-7.10%	-4.27%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	58.75%	63.19%	63.11%	62.51%	60.76%	54.02%	54.75%	57.65%	61.70%	62.49%	60.59%
EBITDA Margin	61.24%	65.81%	59.53%	57.70%	48.51%	52.58%	44.61%	49.36%	57.18%	57.52%	45.20%
Operating Margin	32.93%	41.20%	34.14%	32.68%	21.87%	20.95%	12.20%	18.67%	29.66%	29.57%	15.97%
EBIT Margin	32.93%	41.20%	34.14%	32.68%	21.87%	20.95%	12.20%	18.67%	29.66%	29.57%	15.97%
Profit (Net Income) Margin	15.09%	21.33%	19.12%	13.50%	5.86%	6.89%	1.36%	6.37%	15.05%	8.26%	7.49%
Tax Burden Percent	71.69%	68.38%	75.67%	67.38%	59.92%	72.59%	77.42%	70.38%	72.54%	58.42%	77.35%
Interest Burden Percent	63.94%	75.72%	74.02%	61.29%	44.72%	45.31%	14.40%	48.50%	69.96%	47.79%	60.66%
Effective Tax Rate	28.31%	31.62%	24.33%	32.62%	40.08%	27.41%	22.58%	29.62%	27.46%	41.58%	22.65%
Return on Invested Capital (ROIC)	18.86%	25.11%	23.77%	22.56%	10.00%	13.02%	8.93%	14.19%	18.48%	16.40%	12.53%
ROIC Less NNEP Spread (ROIC-NNEP)	16.51%	22.79%	21.43%	19.06%	8.01%	10.14%	5.90%	11.23%	16.32%	13.07%	10.69%
Return on Net Nonoperating Assets (RNNOA)	43.57%	51.46%	44.27%	32.35%	22.42%	25.11%	12.26%	21.55%	40.19%	27.45%	20.00%
Return on Equity (ROE)	62.43%	76.57%	68.04%	54.91%	32.43%	38.13%	21.19%	35.74%	58.66%	43.85%	32.53%
Cash Return on Invested Capital (CROIC)	36.46%	43.04%	51.55%	49.10%	-34.05%	-34.07%	-36.58%	-34.76%	36.50%	39.21%	40.58%
Operating Return on Assets (OROA)	15.13%	20.15%	16.62%	16.62%	9.32%	9.42%	5.90%	9.98%	13.85%	13.90%	7.74%
Return on Assets (ROA)	6.94%	10.43%	9.31%	6.86%	2.50%	3.10%	0.66%	3.41%	7.03%	3.88%	3.63%
Return on Common Equity (ROCE)	62.43%	76.57%	68.04%	54.91%	32.43%	38.13%	21.19%	35.74%	58.66%	43.85%	32.53%
Return on Equity Simple (ROE_SIMPLE)	5.04%	0.00%	41.99%	46.12%	37.82%	0.00%	18.72%	0.00%	0.00%	0.00%	0.00%
Net Operating Profit after Tax (NOPAT)	32	42	37	32	21	28	17	25	45	35	24
NOPAT Margin	23.60%	28.17%	25.83%	22.02%	13.10%	15.21%	9.45%	13.14%	21.51%	17.28%	12.35%
Net Nonoperating Expense Percent (NNEP)	2.35%	2.32%	2.34%	3.50%	2.00%	2.88%	3.03%	2.96%	2.16%	3.33%	1.84%
Return On Investment Capital (ROIC_SIMPLE)	-	4.89%	-	-	-	2.49%	1.53%	2.34%	4.16%	3.15%	2.11%
Cost of Revenue to Revenue	41.25%	36.81%	36.89%	37.49%	39.24%	45.98%	45.25%	42.35%	38.30%	37.51%	39.41%
SG&A Expenses to Revenue	25.82%	22.00%	28.97%	29.83%	38.89%	34.68%	42.99%	39.17%	32.05%	32.92%	44.62%
R&D to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Expenses to Revenue	25.82%	22.00%	28.97%	29.83%	38.89%	33.07%	42.55%	38.98%	32.04%	32.91%	44.62%
Earnings before Interest and Taxes (EBIT)	45	62	49	47	35	38	22	35	62	61	31
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	84	99	86	84	77	96	79	93	120	118	87
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	4.34	5.14	5.70	4.86	5.31	4.04	4.01	4.09	4.01	4.85	3.36
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Revenue (P/Rev)	1.42	1.77	2.23	1.83	2.08	1.46	1.41	1.34	1.46	1.88	1.32
Price to Earnings (P/E)	86.10	20.84	13.57	10.55	14.05	13.35	21.41	26.20	18.86	23.28	14.01
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	1.16%	4.80%	7.37%	9.48%	7.12%	7.49%	4.67%	3.82%	5.30%	4.30%	7.14%
Enterprise Value to Invested Capital (EV/IC)	2.02	2.46	2.99	2.69	2.03	1.75	1.80	1.88	2.06	2.61	2.07
Enterprise Value to Revenue (EV/Rev)	2.16	2.40	2.77	2.31	3.33	2.56	2.39	2.17	2.12	2.41	1.79
Enterprise Value to EBITDA (EV/EBITDA)	4.19	4.20	4.56	3.79	5.77	4.72	4.71	4.44	4.14	4.60	3.42
Enterprise Value to EBIT (EV/EBIT)	10.11	8.15	8.19	6.55	10.32	9.52	11.15	11.80	10.22	10.49	7.57
Enterprise Value to NOPAT (EV/NOPAT)	23.80	12.81	11.41	9.26	14.91	13.56	16.53	17.25	14.14	15.45	10.93
Enterprise Value to Operating Cash Flow (EV/OCF)	4.42	4.95	5.08	4.82	10.31	7.89	7.98	7.53	5.52	5.72	4.32
Enterprise Value to Free Cash Flow (EV/FCFF)	4.74	4.97	4.95	4.83	0.00	0.00	0.00	0.00	4.99	5.84	4.48
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	3.98	3.41	2.80	2.55	3.83	3.85	3.68	3.54	2.94	2.74	2.63
Long-Term Debt to Equity	2.95	2.48	1.98	1.71	3.43	3.44	3.30	3.27	2.71	2.59	2.47
Financial Leverage	2.64	2.26	2.07	1.70	2.80	2.48	2.08	1.92	2.46	2.10	1.87
Leverage Ratio	6.32	5.94	5.79	5.43	6.81	6.62	6.01	5.90	6.37	6.26	6.00
Compound Leverage Factor	4.04	4.50	4.29	3.33	3.04	3.00	0.87	2.86	4.46	2.99	3.64
Debt to Total Capital	79.90%	77.34%	73.72%	71.85%	79.28%	79.39%	78.62%	77.99%	74.62%	73.27%	72.42%
Short-Term Debt to Total Capital	20.60%	21.25%	21.69%	23.83%	8.27%	8.42%	8.13%	6.12%	5.97%	4.13%	4.43%
Long-Term Debt to Total Capital	59.30%	56.09%	52.03%	48.02%	71.00%	70.96%	70.50%	71.87%	68.66%	69.14%	67.99%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	20.10%	22.66%	26.28%	28.15%	20.72%	20.61%	21.38%	22.01%	25.38%	26.73%	27.58%
Debt to EBITDA	2.52	2.06	1.81	1.57	2.59	2.57	2.57	2.39	2.09	2.02	1.96
Net Debt to EBITDA	1.44	1.10	0.89	0.80	2.17	2.02	1.92	1.68	1.30	1.03	0.91
Long-Term Debt to EBITDA	1.87	1.50	1.28	1.05	2.32	2.30	2.30	2.20	1.92	1.90	1.84
Debt to NOPAT	14.31	6.28	4.52	3.84	6.69	7.39	8.99	9.27	7.12	6.78	6.27
Net Debt to NOPAT	8.18	3.36	2.21	1.95	5.61	5.82	6.72	6.54	4.43	3.45	2.90
Long-Term Debt to NOPAT	10.62	4.56	3.19	2.56	5.99	6.61	8.06	8.54	6.55	6.40	5.89
Altman Z-Score	0.82	1.11	1.35	1.26	0.81	0.68	0.75	0.87	1.11	1.34	1.17
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	1.16	1.17	1.21	1.11	0.97	0.95	1.08	1.18	1.36	1.57	1.71
Quick Ratio	1.05	1.07	1.10	0.99	0.76	0.77	0.88	0.94	1.15	1.36	1.50
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	232	210	217	164	-380	-343	-336	-292	253	236	212
Operating Cash Flow to CapEx	113,873.85%	44,718.29%	10,904.40%	24,962.22%	-3,688.11%	14,849.82%	6,942.11%	111,444.62%	41,722.34%	17,858.93%	21,152.96%
Free Cash Flow to Firm to Interest Expense	11.17	10.88	12.53	7.22	-16.87	-15.13	-16.17	-14.26	11.64	6.69	13.35
Operating Cash Flow to Interest Expense	3.56	3.80	3.57	2.96	-0.40	3.74	2.66	3.54	3.60	3.49	3.60
Operating Cash Flow Less CapEx to Interest Expense	3.56	3.80	3.54	2.95	-0.41	3.71	2.63	3.54	3.59	3.47	3.58
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.46	0.49	0.49	0.51	0.43	0.45	0.48	0.53	0.47	0.47	0.49
Accounts Receivable Turnover	2.90	3.13	3.20	3.28	2.92	3.09	3.29	3.56	3.27	3.55	3.48
Inventory Turnover	5.37	6.10	7.07	8.14	6.25	7.49	8.21	9.28	8.51	8.30	7.83
Fixed Asset Turnover	30.04	31.93	33.02	34.93	38.34	41.66	45.33	50.72	56.37	59.26	62.43
Accounts Payable Turnover	47.00	39.49	50.31	90.83	66.39	40.25	23.55	46.04	60.04	43.49	25.38
Days Sales Outstanding (DSO)	125.95	116.77	113.90	111.19	124.96	117.94	110.83	102.45	111.47	102.84	104.84
Days Inventory Outstanding (DIO)	67.95	59.80	51.66	44.81	58.38	48.76	44.47	39.34	42.87	43.98	46.60
Days Payable Outstanding (DPO)	7.77	9.24	7.25	4.02	5.50	9.07	15.50	7.93	6.08	8.39	14.38
Cash Conversion Cycle (CCC)	186.13	167.33	158.30	151.99	177.84	157.63	139.80	133.86	148.26	138.43	137.06
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	584	552	526	497	985	923	879	813	777	722	691
Invested Capital Turnover	0.80	0.89	0.92	1.02	0.76	0.86	0.95	1.08	0.86	0.95	1.01
Increase / (Decrease) in Invested Capital	-200	-168	-180	-132	401	370	353	316	-208	-200	-188
Enterprise Value (EV)	1,183	1,360	1,571	1,335	1,996	1,618	1,584	1,531	1,605	1,884	1,429
Market Capitalization	776	1,004	1,266	1,053	1,245	924	940	950	1,102	1,464	1,050
Book Value per Share	$5.15	$5.99	$6.87	$6.62	$7.27	$7.10	$7.45	$7.22	$8.72	$9.54	$9.84
Tangible Book Value per Share	($11.84)	($11.04)	($9.25)	($8.25)	($26.65)	($25.58)	($23.89)	($21.66)	($18.92)	($16.25)	($14.09)
Total Capital	890	863	845	769	1,130	1,110	1,097	1,055	1,083	1,129	1,133
Total Debt	711	667	623	553	896	881	862	823	808	827	820
Total Long-Term Debt	528	484	440	369	803	788	773	758	744	780	770
Net Debt	406	357	305	281	751	694	645	581	502	420	379
Capital Expenditures (CapEx)	0.07	0.16	0.57	0.27	0.24	0.57	0.80	0.07	0.19	0.69	0.27
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-49	-48	-42	-40	-67	-121	-88	-93	-80	-109	-81
Debt-free Net Working Capital (DFNWC)	256	263	276	232	78	66	130	149	226	298	361
Net Working Capital (NWC)	72	80	93	48	-16	-27	41	85	161	251	311
Net Nonoperating Expense (NNE)	12	10	9.73	12	12	15	14	13	14	19	9.40
Net Nonoperating Obligations (NNO)	405	357	304	280	751	694	645	581	502	420	379
Total Depreciation and Amortization (D&A)	39	37	37	36	42	58	58	58	58	57	57
Debt-free, Cash-free Net Working Capital to Revenue	-8.92%	-8.39%	-7.39%	-6.90%	-11.19%	-19.24%	-13.19%	-13.12%	-10.59%	-13.91%	-10.14%
Debt-free Net Working Capital to Revenue	46.80%	46.41%	48.71%	40.20%	13.00%	10.50%	19.57%	21.11%	29.79%	38.17%	45.32%
Net Working Capital to Revenue	13.26%	14.06%	16.37%	8.41%	-2.61%	-4.32%	6.15%	11.97%	21.26%	32.21%	39.02%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.61	$0.95	$0.86	$0.60	$0.29	$0.39	$0.08	$0.38	$1.00	$0.52	$0.45
Adjusted Weighted Average Basic Shares Outstanding	33.74M	33.74M	32.33M	32.43M	32.26M	32.27M	31.79M	31.81M	31.57M	31.71M	32.09M
Adjusted Diluted Earnings per Share	$0.53	$0.93	$0.71	$0.52	$0.27	$0.36	$0.07	$0.34	$0.84	$0.48	$0.40
Adjusted Weighted Average Diluted Shares Outstanding	42.06M	41.79M	41.44M	40.38M	40.16M	40.42M	32.84M	39.08M	39.44M	39.70M	40.07M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	32.61M	31.96M	32.72M	32.21M	32.25M	31.49M	32.14M	31.50M	31.61M	31.75M	32.43M
Normalized Net Operating Profit after Tax (NOPAT)	32	42	37	32	21	28	16	24	45	35	24
Normalized NOPAT Margin	23.60%	28.17%	25.83%	22.02%	13.10%	15.21%	9.10%	13.01%	21.50%	17.27%	12.35%
Pre Tax Income Margin	21.05%	31.19%	25.27%	20.03%	9.78%	9.49%	1.76%	9.06%	20.75%	14.13%	9.68%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	2.17	3.20	2.85	2.08	1.55	1.68	1.04	1.72	2.85	1.72	1.95
NOPAT to Interest Expense	1.55	2.19	2.16	1.40	0.93	1.22	0.81	1.21	2.07	1.01	1.51
EBIT Less CapEx to Interest Expense	2.16	3.19	2.82	2.07	1.53	1.66	1.00	1.71	2.84	1.70	1.93
NOPAT Less CapEx to Interest Expense	1.55	2.18	2.13	1.39	0.92	1.20	0.77	1.20	2.06	0.99	1.49
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	639.32%	155.75%	80.39%	110.12%	67.72%	86.75%	0.00%	138.21%	85.77%	39.93%	0.00%

Financials Breakdown Chart

Key Financial Trends

Here are the top 10 trends from Collegium Pharmaceutical (NASDAQ: COLL) across the last four years, focused on revenue, profitability, cash flow, and leverage. Bullets are ordered with positives first, then neutral observations, then negatives.

Strong cash flow: Net cash from continuing operating activities in Q4 2025 was about $122.1 million, signaling robust quarterly cash generation.
Revenue growth in latest quarter: Q4 2025 revenue was about $205.4 million, up from about $181.9 million in Q4 2024.
Solid quarterly profits: Net income from continuing operations was $31.5 million in Q3 2025 and $16.96 million in Q4 2025, with diluted EPS of $0.84 (Q3) and $0.48 (Q4).
Healthy gross margin: Q4 2025 gross margin is around 62% (128.38 million gross profit on 205.45 million revenue).
Financing flexibility: Q4 2025 included a debt issuance of about $565.2 million, offset by repayments, indicating access to capital markets as needed.
Significant intangible asset base: Intangible assets (~$725 million) and goodwill (~$146 million in recent periods) create a sizable asset footprint and potential impairment risk if conditions change.
Balance sheet capacity: Total assets near $1.61 billion and total liabilities around $1.33 billion, with equity around $275 million in late 2025, suggesting a workable but leveraged balance sheet.
Financing activity mix: Net cash from financing activities has been negative in recent quarters, reflecting ongoing debt management and capital allocation actions.
Debt burden remains sizable: Long-term debt sits around $743–$758 million across 2025 periods, contributing to ongoing leverage and interest costs.
Interest expense elevated: Q4 2025 interest expense was about $35.3 million, adding to financing costs and pressuring net income during softer revenue periods.

05/24/26 10:27 PM ETAI Generated. May Contain Errors.

Collegium Pharmaceutical Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Collegium Pharmaceutical's fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Collegium Pharmaceutical's net income appears to be on a downward trend, with a most recent value of $62.87 million in 2025, falling from -$27.26 million in 2015. The previous period was $69.19 million in 2024. See where experts think Collegium Pharmaceutical is headed by visiting Collegium Pharmaceutical's forecast page.

Collegium Pharmaceutical's total operating income in 2025 was $179.64 million, based on the following breakdown:

Total Gross Profit: $463.26 million
Total Operating Expenses: $283.62 million

Over the last 10 years, Collegium Pharmaceutical's total revenue changed from $0.00 in 2015 to $780.57 million in 2025, a change of 78,056,700,000.0%.

Collegium Pharmaceutical's total liabilities were at $1.36 billion at the end of 2025, a 5.5% decrease from 2024, and a 10,616.1% increase since 2015.

In the past 10 years, Collegium Pharmaceutical's cash and equivalents has ranged from $70.57 million in 2024 to $238.95 million in 2023, and is currently $231.25 million as of their latest financial filing in 2025.

Over the last 10 years, Collegium Pharmaceutical's book value per share changed from 4.11 in 2015 to 9.54 in 2025, a change of 132.1%.

Related Companies

Financial statements for NASDAQ:COLL last updated on 5/12/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Collegium Pharmaceutical (COLL) Financials

Financials Breakdown Chart

Key Financial Trends

Collegium Pharmaceutical Financials - Frequently Asked Questions

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Collegium Pharmaceutical (COLL) Financials

Annual Income Statements for Collegium Pharmaceutical

Quarterly Income Statements for Collegium Pharmaceutical

Annual Cash Flow Statements for Collegium Pharmaceutical

Quarterly Cash Flow Statements for Collegium Pharmaceutical

Annual Balance Sheets for Collegium Pharmaceutical

Quarterly Balance Sheets for Collegium Pharmaceutical

Annual Metrics And Ratios for Collegium Pharmaceutical

Quarterly Metrics And Ratios for Collegium Pharmaceutical

Financials Breakdown Chart

Key Financial Trends

Collegium Pharmaceutical Financials - Frequently Asked Questions

When does Collegium Pharmaceutical's financial year end?

How has Collegium Pharmaceutical's net income changed over the last 10 years?

What is Collegium Pharmaceutical's operating income?

How has Collegium Pharmaceutical's revenue changed over the last 10 years?

How much debt does Collegium Pharmaceutical have?

How much cash does Collegium Pharmaceutical have?

How has Collegium Pharmaceutical's book value per share changed over the last 10 years?

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools